RYSTIGGO is the first and only FDA-approved targeted treatment for both
anti-AChR and anti-MuSK antibody-positive adult patients with generalized myasthenia gravis (gMG)

Rapid efficacy
in action

for a broad population
of patients with gMG1,2*

In a clinical study, RYSTIGGO demonstrated statistically significant 
improvements vs placebo in MG-ADL total score at Week 6 (-3.4 vs. -0.8; P<0.001),
with improvements observed as early as Week 1.1

Explore THE data

RYSTIGGO is the first and only FDA-approved targeted treatment for both anti-AChR and anti-MuSK antibody-positive adult patients with generalized myasthenia gravis (gMG)

In a clinical study, RYSTIGGO demonstrated clinically meaningful and statistically significant improvements in MG-ADL vs placebo at Week 6 (-2.6, P<0.001), with rapid effect as early as Week 1.1

Explore THE data

Statistically significant improvements

across key gMG outcome measures vs placebo at Week 6 (Day 43)1

VIEW THE RESULTS

First and only
targeted treatment

FDA-approved for adult patients with anti-MuSK Ab+ gMG1

SEE MuSK DATA

Once-weekly subcutaneous infusions

delivered in a 6-week treatment cycle by a healthcare professional1

LEARN MORE

The efficacy of RYSTIGGO for the treatment of adult anti-AChR Ab+ and anti-MuSK Ab+ gMG patients was established in an up to 18-week, multicenter, randomized, double-blind, placebo-controlled study. In the study, 200 adult patients were randomized 1:1:1 to receive weight-tiered doses of RYSTIGGO (n=133), either 7 mg/kg of RYSTIGGO (n=66) or 10 mg/kg (n=67), or placebo (n=67).1

 

*The clinical study included adult patients who were AChR or MuSK autoantibody positive, and who had MGFA Class II-IVa disease, an MG-ADL score of ≥3 (with ≥3 points from non-ocular symptoms), serum immunoglobulin G levels ≥5.5 gL, and who were on a stable dose of MG therapy prior to screening.1

Ab+=antibody positive; AChR=acetylcholine receptor; gMG=generalized myasthenia gravis; MG-ADL=Myasthenia Gravis Activities of Daily Living; MGFA=Myasthenia Gravis Foundation of America; MuSK=muscle-specific tyrosine kinase.

References:

  1. RYSTIGGO [Prescribing Information]. Smyrna, GA: UCB, Inc.
  2. Bril V, Drużdż A, Grosskreutz J, et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol. 2023;22(5):383-394. doi:10.1016/S1474-4422(23)00077-7